In vitro and in vivo evaluation of a preservative-free cationic emulsion of latanoprost in corneal wound healing models

Cornea

Volumn 31, Issue 11, 2012, Pages 1319-1329

  Liang, Hong ^a,b,c,d   Baudouin, Christophe ^a,b,c,d,e,f   Daull, Philippe ^g   Garrigue, Jean Sébastien ^g   Buggage, Ronald ^g   Brignole Baudouin, Françoise ^a,b,c,d,e,h  

^a INSERM   (France)

^b SORBONNE UNIVERSITÉ   (France)

^c CNRS   (France)

^d CENTRE HOSPITALIER NATIONAL D OPHTALMOLOGIE DES QUINZE VINGTS   (France)

^e ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

^f LABORATOIRE DES SCIENCES DU CLIMAT ET DE L ENVIRONNEMENT   (France)

^g Novagali Pharma   (France)

^h Centre Universitaire des Saints Pères   (France)

Author keywords

cationic emulsions; cornea; cytotoxicity; latanoprost

Indexed keywords

KI 67 ANTIGEN; LATANOPROST;

ARTICLE; CATIONIC EMULSION; CELL MIGRATION; CELL PROLIFERATION; CONTROLLED STUDY; CORNEA EPITHELIUM; CORNEA INJURY; CORNEAL WOUND HEALING; CYTOTOXICITY; DRUG SCREENING; EMULSION; EPITHELIUM CELL; GLAUCOMA; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; PRIORITY JOURNAL; SLIT LAMP; WOUND CLOSURE; WOUND HEALING;

ANIMALS; ANTIHYPERTENSIVE AGENTS; BENZALKONIUM COMPOUNDS; CELL PROLIFERATION; CELLS, CULTURED; CONJUNCTIVA; CORNEA; DISEASE MODELS, ANIMAL; DRUG EVALUATION, PRECLINICAL; EMULSIONS; EPITHELIUM, CORNEAL; EYE INJURIES; HUMANS; KI-67 ANTIGEN; MALE; MICROSCOPY, CONFOCAL; MUCIN 5AC; PRESERVATIVES, PHARMACEUTICAL; PROSTAGLANDINS F, SYNTHETIC; RATS; WOUND HEALING;

EID: 84867401978     PISSN: 02773740     EISSN: 15364798     Source Type: Journal    
DOI: 10.1097/ICO.0b013e318255a7f8     Document Type: Article

References (37)

1. Stein JD, Kim DS, Niziol LM, et al. Differences in rates of glaucoma among Asian Americans and other racial groups, and among various Asian ethnic groups. Ophthalmology. 2011;118:1031-1037.
2. Fechtner RD, Godfrey DG, Budenz D, et al. Prevalence of ocular surface complaints in patients with glaucoma using topical intraocular pressurelowering medications. Cornea. 2010;29:618-621.
3. Leung EW, Medeiros FA, Weinreb RN. Prevalence of ocular surface disease in glaucoma patients. J Glaucoma. 2008;17:350-355.
4. Tsai JH, Derby E, Holland EJ, et al. Incidence and prevalence of glaucoma in severe ocular surface disease. Cornea. 2006;25:530-532.
5. Erb C, Gast U, Schremmer D. German register for glaucoma patients with dry eye. I. Basic outcome with respect to dry eye. Graefes Arch Clin Exp Ophthalmol. 2008;246:1593-1601.
6. Hopes M, Broadway D. Preservative-free treatment in glaucoma is a sensible and realistic aim for the future. Eur Ophthalmic Rev. 2010;4:23-28.
7. Baudouin C, Hamard P, Liang H, et al. Conjunctival epithelial cell expression of interleukins and inflammatory markers in glaucoma patients treated over the long term. Ophthalmology. 2004;111:2186-2192.
8. Baudouin C, Liang H, Hamard P, et al. The ocular surface of glaucoma patients treated over the long term expresses inflammatory markers related to both T-helper 1 and T- helper 2 pathways. Ophthalmology. 2008;115:109-115.
9. Martone G, Frezzotti P, Tosi GM, et al. An in vivo confocal microscopy analysis of effects of topical antiglaucoma therapy with preservative on corneal innervation and morphology. Am J Ophthalmol. 2009;147:725-735.
10. De Saint Jean M, Brignole F, Bringuier AF, et al. Effects of benzalkonium chloride on growth and survival of Chang conjunctival cells. Invest Ophthalmol Vis Sci. 1999;40:619-630.
11. Neville R, Dennis P, Sens D, et al. Preservative cytotoxicity to cultured corneal epithelial cells. Curr Eye Res. 1986;5:367-372.
12. Lapalus P, Ettaiche M, Fredj-Reygrobellet D, et al. Cytotoxicity studies in ophthalmology. Lens Eye Toxic Res. 1990;7:231-242.
13. Ayaki M, Iwasawa A. Cytotoxicity of prostaglandin analog eye drops preserved with benzalkonium chloride in multiple corneoconjunctival cell lines. Clin Ophthalmol. 2010;4:919-924.
14. Liang H, Brignole-Baudouin F, Rabinovich-Guilatt L, et al. Reduction of quaternary ammonium-induced ocular surface toxicity by emulsions: An in vivo study in rabbits. Mol Vis. 2008;14:204-216.
15. Kahook MY, Noecker R. Quantitative analysis of conjunctival goblet cells after chronic application of topical drops. Adv Ther. 2008;25: 743-751.
16. Pauly A, Brignole-Baudouin F, Labbe A, et al. New tools for the evaluation of toxic ocular surface changes in the rat. Invest Ophthalmol Vis Sci. 2007;48:5473-5483.
17. Labbe A, Pauly A, Liang H, et al. Comparison of toxicological profiles of benzalkonium chloride and polyquaternium-1: An experimental study. J Ocul Pharmacol Ther. 2006;22:267-278.
18. Brasnu E, Brignole-Baudouin F, Riancho L, et al. In vitro effects of preservative-free tafluprost and preserved latanoprost, travoprost, and bimatoprost in a conjunctival epithelial cell line. Curr Eye Res. 2008; 33:303-312.
19. Liang H, Baudouin C, Pauly A, et al. Conjunctival and corneal reactions in rabbits following short- and repeated exposure to preservative-free tafluprost, commercially available latanoprost and 0.02% benzalkonium chloride. Br J Ophthalmol. 2008;92:1275-1282.
20. Ammar DA, Noecker RJ, Kahook MY. Effects of benzalkonium chloride- preserved, polyquad-preserved, and sofZia-preserved topical glaucoma medications on human ocular epithelial cells. Adv Ther. 2010;27: 837-845.
21. Kahook MY, Ammar DA. In vitro toxicity of topical ocular prostaglandin analogs and preservatives on corneal epithelial cells. J Ocul Pharmacol Ther. 2010;26:259-263.
22. Gupta SR, Myers JS, Cruz CC, et al. Effects of latanoprost versus travoprost with sofzia on the ocular surface of patients. Invest Ophthalmol Vis Sci. 2011;229:109. ARVO abstract
23. Horsley MB, Kahook MY. Effects of prostaglandin analog therapy on the ocular surface of glaucoma patients. Clin Ophthalmol. 2009;3:291-295.
24. Daull P, Lallemand F, Lambert G, et al. Distribution of cyclosporine A in ocular tissues after topical administration of cyclosporine A-cationic emulsion to pigmented rabbits. Invest Ophthalmol Vis Sci. 2011;186: 376. ARVO abstract
25. Garrigue JS, Lambert G, Rabinovich L, et al. A comparative study of latanoprost- cationic emulsion (Catioprost) and latanoprost aqueous solution (Xalatan) in preclinical efficacy and safety models. Invest Ophthalmol Vis Sci. 2011;230:109. ARVO abstract
26. Liang H, Baudouin C, Faure MO, et al. Comparison of the ocular tolerability of a latanoprost cationic emulsion versus conventional formulations of prostaglandins: An in vivo toxicity assay. Mol Vis. 2009; 15:1690-1699.
27. Baudouin C. A new approach for better comprehension of diseases of the ocular surface [in French]. J Fr Ophtalmol. 2007;30:239-246.
28. Bandeen-Roche K, Munoz B, Tielsch JM, et al. Self-reported assessment of dry eye in a population-based setting. Invest Ophthalmol Vis Sci. 1997; 38:2469-2475.
29. Araki-Sasaki K, Ohashi Y, Sasabe T, et al. An SV40-immortalized human corneal epithelial cell line and its characterization. Invest Ophthalmol Vis Sci. 1995;36:614-621.
30. Dutot M, Liang H, Pauloin T, et al. Effects of toxic cellular stresses and divalent cations on the human P2-7 cell death receptor. Mol Vis. 2008; 14:889-897.
31. Liang H, Brignole-Baudouin F, Labbe A, et al. LPS-stimulated inflammation and apoptosis in corneal injury models. Mol Vis. 2007;13:1169-1180.
32. Baudouin C, Labbe A, Liang H, et al. Preservatives in eyedrops: The good, the bad and the ugly. Prog Retin Eye Res. 2010;29:312-334.
33. Lin Z, Liu X, Zhou T, et al. A mouse dry eye model induced by topical administration of benzalkonium chloride. Mol Vis. 2011;17:257-264.
34. Sivak JM, Fini ME. MMPs in the eye: Emerging roles for matrix metalloproteinases in ocular physiology. Prog Retin Eye Res. 2002;21:1-14.
35. Nakano Y, Oyamada M, Dai P, et al. Connexin43 knockdown accelerates wound healing but inhibits mesenchymal transition after corneal endothelial injury in vivo. Invest Ophthalmol Vis Sci. 2008;49:93-104.
36. Hong J, Bielory L. Allergy to ophthalmic preservatives. Curr Opin Allergy Clin Immunol. 2009;9:447-453.
37. Xiong C, Chen D, Liu J, et al. A rabbit dry eye model induced by topical medication of a preservative benzalkonium chloride. Invest Ophthalmol Vis Sci. 2008;49:1850-1856.